Novartis: EU approves breast cancer drug.
(CercleFinance.com) - The European Commission has approved Novartis' drug Kisqali as first-line treatment for HR+/HER2- breast cancer in combination with any aromatase inhibitor, the drugmaker said on Thursday.
Novartis stated that Kisqali has been approved in combination for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer as an initial endocrine-based therapy.
In a trial that included 668 women with HR+/HER2- cancer, Kisqali plus Sandoz's letrozole, an aromatase inhibitor, reduced the risk of progression or death by 43% over letrozole alone.
Novartis also said this Thursday that Bertrand Bodson, the chief digital and marketing officer of Sainsbury's Argos, had been appointed to the new role of chief digital officer, reporting to CEO Joseph Jimenez.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Novartis stated that Kisqali has been approved in combination for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer as an initial endocrine-based therapy.
In a trial that included 668 women with HR+/HER2- cancer, Kisqali plus Sandoz's letrozole, an aromatase inhibitor, reduced the risk of progression or death by 43% over letrozole alone.
Novartis also said this Thursday that Bertrand Bodson, the chief digital and marketing officer of Sainsbury's Argos, had been appointed to the new role of chief digital officer, reporting to CEO Joseph Jimenez.
Copyright (c) 2017 CercleFinance.com. All rights reserved.